BioSerenity announces 1 million patients cared for

Paris, July 21, 2023

BioSerenity, designer of innovative medical solutions in electrophysiology, has just reached a significant milestone in patient monitoring and diagnosis! To date, one million patients have benefited from its medical technologies in the fields of Neurology and Sleep Disorders.

BioSerenity, designer of innovative electrophysiology medical solutions, has reached a significant milestone in patient monitoring and diagnosis.

BioSerenity’s mission

The birth of BioSerenity is directly linked to the difficulties encountered in the care of epilepsy patients. Patients generally face major obstacles when it comes to obtaining an accurate diagnosis of their disease. It is crucial to understand that the diagnosis of epilepsy relies on an electrophysiological examination of the brain, known as an EEG (Electroencephalography). However, access to the EEG is often considered difficult, due to the complexity of both performing and interpreting the examination. This situation generates diagnostic errancy for patients, delaying appropriate medical management and additional costs for the healthcare system.

In 2014, in response to this problem, BioSerenity is committed to developing innovative solutions to democratize access to EEG. This optimization of electrophysiological diagnosis was then extended, notably in the field of Sleep Disorders.

Since then, BioSerenity’s teams have worked relentlessly to make electrophysiology accessible to all, thereby combating therapeutic erraticism, and to provide healthcare professionals with IT tools for better management, whether via LR, a SaaS platform for managing sleep clinics and ventilatory polygraphs, or via BioSerenity A.I., an Artificial Intelligence diagnostic aid for Neurology and Sleep Disorders.

Since its creation in 2014, within the Institut du Cerveau et de la Moelle Épinière (ICM) at the Pitié-Salpêtrière Hospital (AP-HP, Paris), the company has established itself as a benchmark in the performance and remote interpretation of electrophysiological examinations.Thanks to its recognized expertise, BioSerenity’s teams of engineers, researchers and healthcare professionals put their know-how at the service of today’s medicine, enabling the company to collaborate with over 300 hospitals and 10,000 healthcare professionals in France and the United States.

“1 million patients have been diagnosed and are now being monitored – it’s a great victory!We’re proud of this development and ready to contribute even more. DeepTech involving physical devices, precision electronics, a software platform and Artificial Intelligence is quite a challenge, and one that our teams have succeeded in meeting with the help of the medical community”, said Pierre- Yves Frouin, CEO of BioSerenity.

About BioSerenity is …

  • NEURONAUTE, a miniature, mobile ambulatory EEG device designed to make examinations easier and more efficient, marketed on three continents
  • 12 Sleep Exploration Centers throughout France
  • 3 sleep research laboratories based in the United States
  • 2 production and tele-interpretation services, for faster, more accurate diagnosis in Neurology and Sleep.
  • One of the largest data repositories in Neurology and Sleep Disorders, with over 800,000 PSG data recordings to date, for example
  • Access to electrophysiological diagnosis even in the most remote areas of the world, thanks to neurological tele-interpretation (in the French West Indies, for example)
  • And above all, 1 million patients have been monitored and diagnosed since the company was founded.

BioSerenity opens up new perspectives in electrophysiological monitoring and diagnosis. Would you like to find out more?

More info :

Press Contact

André Pitié